Diabetic cardiomyopathy

Diabetic cardiomyopathy is defined by the existence of abnormal myocardial structure and performance in the absence of other cardiac risk factors, such as coronary artery disease, hypertension, and significant valvular disease, in individuals with diabetes mellitus.

  • AstraZeneca’s Onglyza (saxagliptin)
  • AstraZeneca’s Kombiglyze (saxagliptin and metformin extended release)
  • Takeda’s Nesina (alogliptin)
  • Takeda’s Kazano (alogliptin and metformin)
  • Takeda’s Oseni (alogliptin and pioglitazone)

Related Conference of Diabetic cardiomyopathy

January 12-13, 2026

12th International Heart Conference

Dubai, UAE
March 18-19, 2026

15th World Heart Congress

Paris, France
March 23-24, 2026

37th Annual Cardiologists Conference

London, UK
March 23-24, 2026

41st World Cardiology Conference

London, UK
April 06-07, 2026

40th World Congress on Heart Diseases

Paris, France
April 08-29, 2026

9th Annual Heart Rhythm Conference

Vienna, Austria
April 13-14, 2026

9th World Heart and Brain Conference

Tokyo, Japan
April 15-16, 2026

8th World Heart Congress

Tokyo, Japan
May 14-15, 2026

5th International Conference on Cardiology

Rome, Italy
May 21-22, 2026

15th World Congress on Cardiology

London, UK
June 15-16, 2026

7th European Summit on Cardiology Research

Zurich, Switzerland
July 29-30, 2026

30th World Cardiology Conference

Paris, France
August 17-18, 2026

4th International Conference on World Heart Care

Toronto, Canada
August 24-25, 2026

15th World Heart Congress

London, UK
August 27-28, 2026

40th European Cardiology Conference

Berlin, Germany

Diabetic cardiomyopathy Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in